Manufacturer of Controlled Substances; Notice of Registration, 10679-10680 [05-4203]
Download as PDF
<![CDATA[
10679
Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices
manufacturer of Cocaine (9041), a basic
class of controlled substance listed in
Schedule II.
The company plans to manufacture a
cocaine derivative to be used as an
intermediate for the production of
Dopascan Injection. Cocaine derivatives
are a Schedule II controlled substance in
the cocaine basic class.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Guilford Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Guilford Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
VerDate jul<14>2003
19:07 Mar 03, 2005
Jkt 205001
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4202 Filed 3–3–05; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
Drug Enforcement Administration
By Notice dated September 16, 2004,
and published in the Federal Register
on September 30, 2004, (69 FR 58542–
58533), Lifepoint, Inc., 10400
Trademark Street, Rancho Cucamonga,
California 91730, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedules I and II:
Drug
Pursuant to section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on November
11, 2004, JFC Technologies, LLC, 100
West Main Street, Bound Brook, New
Jersey 08805, made application by
renewal to the Drug Enforcement
Administration (DEA) for registration as
a bulk manufacturer of the basic class of
controlled substances listed in Schedule
II:
Matthey Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
BILLING CODE 4410–09–P
By Notice dated November 22, 2004
and published in the Federal Register
on December 6, 2004, (69 FR 70470),
Johnson Matthey, Inc., Pharmaceutical
Materials, 2003 Nolte Drive, West
Deptford, New Jersey 08066, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
class of controlled substances listed in
Schedule II.
BILLING CODE 4410–09–P
Diphenozylate (9170) ....................
Hydrocodone (9193) .....................
Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4227 Filed 3–3–05; 8:45 am]
Importer of Controlled Substances;
Notice of Registration
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4198 Filed 3–3–05; 8:45 am]
Drug
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 3, 2005.
Schedule
Phenylacetone (8501) ..................
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
II
II
II
The company plans to import the
listed controlled substances as raw
materials for use in the manufacture of
bulk controlled substances for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Johnson Matthey Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Johnson
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
Drug
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Phencyclidine (7471) ....................
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
Schedule
I
II
II
II
II
II
The company plans to produce small
quantities of controlled substances for
use in drug test kits.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Lifepoint, Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
Lifepoint, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
E:\FR\FM\04MRN1.SGM
04MRN1
10680
Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4222 Filed 3–3–05; 8:45 am]
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4203 Filed 3–3–05; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Pursuant to 21 U.S.C. 958(1), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(b) authorizing the importation
of such substances, provide
manufacturers holding registrations for
the bulk manufacture of the substances
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
December 9, 2004, Lipomed Inc., One
Broadway, Cambridge, Massachusetts
02142, made application by renewal to
the Drug Enforcement Administration
(DEA) for registration as an importer of
the basic classes of controlled
substances:
Drug Enforcement Administration
Importation of Controlled Substances;
Notice of Application
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances Notice of Application
Pursuant to 21 CFR 1301.33(a), Title
21 of the Code of Federal Regulations
(CFR), this is notice that on December
9, 2004, Lin Zhi International Inc., 687
North Pastoria Avenue, Sunnyvale,
California 94085, made application by
renewal to the Drug Enforcement
Administration (DEA) for registration as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedule II.
Drug
Schedule
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
II
II
The company plans to manufacture
the listed controlled substances in bulk
for use in analysis and drug test
standards.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a)
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 3, 2005.
VerDate jul<14>2003
19:07 Mar 03, 2005
Jkt 205001
BILLING CODE 4410–09–P
Drug
Schedule
Cathinone (1235) ..........................
Methaqualone (2565) ...................
Gamma-Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5-Trimethoxyamphetamine
(7390).
4-Bromo-2–5dimethoxyamphetamine (7391).
4-Methyl-2,5dimethoxyamphetamine (7395).
2,5-Dimethoxyamphetamine
(7396).
2,5-Dimethoxy-4ethylamphetamine (7399).
3,4-Methylenedioxyamphetamine
(7400).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4-Methylenedioxymethamphetamine (7405).
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Secobarbital (2315) ......................
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
Drug
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Methadone (9250) ........................
Dextropropoxphene (9273) ..........
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import small
reference standard quantities of finished
commercial product from its sister
company in Switzerland for distribution
to its customers for drug testing and
pharmaceutical research and
development.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file written
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than April 4, 2005.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–43746), all applicants for
registration to import basic class of any
controlled substance in Schedule I or II
are and will continue to be required to
demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
E:\FR\FM\04MRN1.SGM
04MRN1
]]>Agencies
[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Pages 10679-10680]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4203]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated September 16, 2004, and published in the Federal
Register on September 30, 2004, (69 FR 58542-58533), Lifepoint, Inc.,
10400 Trademark Street, Rancho Cucamonga, California 91730, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in Schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Phencyclidine (7471)....................... II
Benzoylecgonine (9180)..................... II
Morphine (9300)............................ II
------------------------------------------------------------------------
The company plans to produce small quantities of controlled
substances for use in drug test kits.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Lifepoint, Inc. to manufacture the listed basic classes of controlled
substances is consistent with the public interest at this time. DEA has
investigated Lifepoint, Inc. to ensure that the company's registration
is consistent with the public interest. The investigation has included
inspection and testing of the company's physical security systems,
verification of the company's compliance with state and
[[Page 10680]]
local laws, and a review of the company's background and history.
Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR
1301.33, the above named company is granted registration as a bulk
manufacturer of the basic classes of controlled substances listed.
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-4203 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P
